He Started a Psychedelics Company. It Sold for $700M.
In a Nutshell
A former Yale board member founded a psychedelics company around methylone after reading Michael Pollan's book, securing patents for PTSD, depression, and anxiety treatment. Methylone was chosen over MDMA because it can be dosed weekly without serotonin depletion or post-use depression, aligning better with standard clinical delivery. The company learned from early industry failures around psychotherapy integration and FDA requirements, positioning itself as a later entrant to avoid the $200M+ costs and regulatory pitfalls that sank predecessors.
These notes were generated by AI and may contain inaccuracies.
At age fifty-four, the speaker had never considered drugs and had no prior experience with them. After reading Michael Pollan's book "How to Change Your Mind," which appeared on The New York Times' list of the 10 best books of 2017, his perspective shifted completely. The book revealed the potential therapeutic applications of psychedelics, supported by academic research showing efficacy for treating PTSD, depression, and anxiety.
While serving on the Yale University Board of Governors, the speaker connected with John Crystal, whose work on ketamine represents seminal research in depression treatment. He also collaborated with Ben Kalmendi, a professor at Yale. The speaker spent a week in the desert with Ben, marking their first in-person meeting. Yale has established the Yale Center for Drug Research, which the speaker supports as one of its largest donors through the Yale Center for Substance Abuse Research.
In 2021, after discussions with Ben Kalmendi, the speaker recognized that moving from nonprofit research to a profitable business model was necessary. FDA approval for a single compound requires approximately $200 to $250 million, making nonprofit funding insufficient. Working with Ben and Blake Mandel from the Alicorp team, they identified methylone as their compound of choice.
Blake Mandel left Alicorp to become the company's CEO. The company was founded around methylone, with significant credit attributed to Ben's contributions. The speaker's first experience with methylone occurred around 2015, obtained with difficulty even on the black market, and was described as a pleasant, gentle, peaceful, and short-lived experience.
From both business and societal impact perspectives, methylone was selected because it was relatively unknown yet showed promising initial results. Key advantages compared to MDMA include the ability to administer methylone once weekly in trials, whereas MDMA cannot be taken weekly due to greater toxicity and serotonin depletion. MDMA users may develop resistance or become unresponsive with frequent use, and some experience post-use depression that is typically absent with methylone. The duration of methylone's effects aligns better with standard healthcare delivery models.
The company secured patents for treating PTSD, depression, and anxiety, providing 20-year exclusivity in these three therapeutic categories. However, due to the $200 million cost per indication, development began with a single indication. Results have been promising within PTSD treatment indicators.
Two years prior, the psychedelics field experienced a "dry spell" making fundraising difficult. The speaker noted that stigma contributed to funding challenges, despite interest from enthusiastic investors. Common industry mistakes included underestimating the complexity of scaling 4-6 hour treatments, which requires additional nursing staff and significantly increases operational costs. The FDA Advisory Committee rejected psychotherapy integration packages, citing inability to evaluate or standardize psychotherapy.
The speaker referenced the principle "the early bird catches the worm, but the second mouse gets the cheese," indicating strategic positioning as a later entrant to avoid pitfalls experienced by earlier companies. This approach was informed by observing ecosystem dynamics and early unexplained errors in the field, including experiences with companies like Lycos regarding psychotherapy integration challenges.
Keep Tim Ferriss in your library
Save the videos and channels worth coming back to, and find them again in one place.
